Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwCAR-T 2023 | Updates in ALL

Bijal Shah, Claire Roddie, Nirav Niranjan Shah and Rebecca Gardner • 14 Apr 2023
iwCAR-T 2023
Acute Lymphoblastic Leukemia Leukemia CAR-T

In this session, Bijal Shah, MD Moffitt Cancer Center, Tampa, FL, Claire Roddie, MD, PhD, University College London Hospitals NHS Foundation Trust, London, UK, Rebecca Gardner, MD, Seattle Children’s Hospital, Seattle, WA, and Nirav Shah, MD, Medical College of Wisconsin, Milwaukee, WI, share the latest advances in CAR-T therapy for acute lymphoblastic leukemia (ALL), exploring strategies to improve CAR-T products. This discussion took place at the 5th International Workshop on CAR-T (iwCAR-T) 2023 held in Scottsdale, AZ.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Bijal Shah

1:33
The impact of prior therapies on the outcomes of patients with R/R ALL treated with CAR-T therapy
Bijal Shah • 8 Sep 2023
1:27
TP53-aberrant MCL: challenges and treatment approaches
Bijal Shah • 8 Sep 2023
1:03
ECOG-E1910 study: clinical benefit of early blinatumomab incorporation in ALL
Bijal Shah • 8 Sep 2023
1:03
An insight into the sequencing of immunotherapies in adults with ALL
Bijal Shah • 8 Sep 2023

More from Claire Roddie

1:28
Insights into the UCL CAR T program
Claire Roddie • 3 Jun 2023
3:38
Mechanisms of resistance to CAR-T in ALL: T-cell fitness, antigen loss and immunological rejection
Claire Roddie • 3 Jun 2023
4:45
Safety and efficacy of obe-cel in R/R adult B-ALL: results of the pivotal FELIX study
Claire Roddie • 3 Jun 2023
5:01
Early safety and efficacy data of AUTO1 in R/R indolent B-cell lymphoma
Claire Roddie • 10 Jun 2021

More from Nirav Niranjan Shah

2:42
Dual-targeted anti-CD19/anti-CD20 CAR T-cells in R/R MCL: insights from a Phase I/II trial
Nirav Niranjan Shah • 11 Dec 2023
1:35
Pirtobrutinib in R/R FL: results from the BRUIN study
Nirav Niranjan Shah • 11 Dec 2023
Novel therapies in NHL: BTK inhibitors & degraders
Nirav Niranjan Shah et al. • 17 Oct 2023
2:13
Phase II trial of split-dose R-CHOP for older patients with DLBCL
Nirav Niranjan Shah • 4 Jun 2023

More from Rebecca Gardner

11:47
What's the latest on CAR-T in ALL?
Bijal Shah et al. • 11 Oct 2019

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals